Rocket Pharmaceuticals, Inc. - Warrant (RCKTW)

In our clinical review of the recent data, all three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol successfully completed the safety observation period without thrombotic microangiopathy, capillary leak syndrome, or other significant safety issues. As we prepare for a broader Danon disease program update and initial patient dosing with RP-A701 in BAG3-DCM in the second half of 2026, clinical execution remains promising, though we are closely monitoring the regulatory pathway with the FDA to rapidly complete the pivotal trials.

Watching the 50-day moving averages and recent tape action, RCKTW has seen severe deterioration, sliding toward penny stock territory around $0.01 with heavy put flow alerts. The technical setup shows extreme price compression at support levels that now double as resistance, signaling profound market uncertainty and mounting selling pressure tied to the expiration clock of September 2, 2026, for these warrants. Risk management requires extreme caution given the deep out-of-the-money reality facing warrant holders.

On our desk, the contrast between the operational milestones and the warrant action is stark. Rocket secured a major win with the FDA accelerated approval of KRESLADI for severe LAD-I, followed by a definitive agreement to monetize the PRV for $180 million, which yielded crucial non-dilutive capital alongside their $144.4 million in cash and investments as of March 31, 2026. However, market sentiment for the derivative side tells a brutal story.